Dr. Sebesta discusses disparities in incontinence product usage, costs

Functional success was achieved in 58% of patients at 5-year follow-up.

“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.

"The goal for this study was to understand, over the lifetime in individuals with spina bifida, what bacteria are present in their urine normally, what bacteria are present when they have a UTI, and what are some important clinical differences we can tease out to help understand which patients should really be treated," says Brendan T. Frainey, MD.

“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.

The approval of vibegron is supported by data from the phase 3 COURAGE trial.

"I hope that [attendees] will be exposed to a community where they feel that they're able to freely ask questions, gain accurate information, and feel heard, validated, and connected," says Lauren E. Corona, MD.